Dysautonomia Differentially Influences the Effect of Affective Pain Perception on Quality of Life in Parkinson’s Disease Patients

Table 2

(a) Bivariant analysis by pain (without/with) . (b) Bivariant analysis by dysautonomic symptoms, .

(a)

	Without pain ()	With pain ()
	Mean (SD)	Mean (SD)
Age	66.10 (8.93)	69.73 (8.48)	0.091
Sex (women%)	15	50.6	0.004
Age at PD diagnosis	58.01 (8.78)	60.45 (9.25)	0.289
Disease duration (years)	8.08 (5.26)	9.29 (5.51)	0.363
SCOPA-AUT	7.45 (4.03)	15.06 (7.39)	<0.001
UPDRS I	2.80 (1.99)	2.92 (2.56)	0.872
UPDRS II	10.00 (4.14)	13.48 (5.77)	0.005
UPDRS III	28.20 (7.54)	32.20 (10.32)	0.106
UPDRS IV	1.75 (1.55)	3.85 (3.27)	0.005
PDQ-39	20.28 (13.34)	32.81 (21.85)	0.033
Daily equivalent levodopa dosage (mg)	419.34 (317.43)	540.08 (329.07)	0.149

(b)

	Low SCOPA (12)	High SCOPA (>12)
	Mean (SD)	Mean (SD)
Age	67.95 (9.37)	70.39 (7.54)	0.413
Sex (women%)	41.4	46.8	0.577
Age at PD diagnosis	59.2 (9.82)	61 (8.31)	0.332
Disease duration (years)	8.76 (5.47)	9.4 (5.48)	0.476
PDQ-39	22.30 (16.38)	40.77 (21.92)	<0.001
UPDRS I	3.34 (2.47)	2.53 (2.39)	0.068
UPDRS II	15.15 (5.21)	10.95 (10.00)	<0.001
UPDRS III	35.94 (8.93)	27.79 (9.27)	<0.001
UPDRS IV	4.26 (3.51)	2.79 (2.63)	0.018
PRIS	6.10 (4.95)	9.91 (4.04)	<0.001
PRIM	1.34 (1.68)	2.60 (1.94)	0.001
PRIA	1.12 (1.35)	2.53 (1.93)	<0.001
PRIT	8.57 (6.92)	15.04 (5.86)	<0.001
Daily equivalent levodopa dosage (mg)	586.97 (48.75)	461.18 (315.94)	0.087